Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7192138rdf:typepubmed:Citationlld:pubmed
pubmed-article:7192138lifeskim:mentionsumls-concept:C0025519lld:lifeskim
pubmed-article:7192138lifeskim:mentionsumls-concept:C0060201lld:lifeskim
pubmed-article:7192138pubmed:issue8lld:pubmed
pubmed-article:7192138pubmed:dateCreated1981-1-26lld:pubmed
pubmed-article:7192138pubmed:abstractTextThe main metabolite of 2-phenyl-4-p-chlorophenylthiazol-5-ylacetic acid (fentiazac) is represented by a p-hydroxylated compound which is formed rapidly and that, still 72 later, can be detected in the general circulation. The p-hydroxylated metabolite is much less toxic than the original molecule from which it derives, being still active from an anti-inflammatory standpoint (its activity being equal to 70--75% of that of fentiazac). The metabolite, which possesses a therapeutic index much higher than that of fentiazac, represents quite an important step in the detoxication processes of the drug and enhances the therapeutic activity of the drug itself.lld:pubmed
pubmed-article:7192138pubmed:languageenglld:pubmed
pubmed-article:7192138pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7192138pubmed:citationSubsetIMlld:pubmed
pubmed-article:7192138pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7192138pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7192138pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7192138pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7192138pubmed:statusMEDLINElld:pubmed
pubmed-article:7192138pubmed:issn0004-4172lld:pubmed
pubmed-article:7192138pubmed:authorpubmed-author:SilvestreWWlld:pubmed
pubmed-article:7192138pubmed:authorpubmed-author:MondinoAAlld:pubmed
pubmed-article:7192138pubmed:authorpubmed-author:ZanoloGGlld:pubmed
pubmed-article:7192138pubmed:authorpubmed-author:FumeroSSlld:pubmed
pubmed-article:7192138pubmed:authorpubmed-author:De MarchiGGlld:pubmed
pubmed-article:7192138pubmed:authorpubmed-author:PedrazziniSSlld:pubmed
pubmed-article:7192138pubmed:issnTypePrintlld:pubmed
pubmed-article:7192138pubmed:volume30lld:pubmed
pubmed-article:7192138pubmed:ownerNLMlld:pubmed
pubmed-article:7192138pubmed:authorsCompleteYlld:pubmed
pubmed-article:7192138pubmed:pagination1253-6lld:pubmed
pubmed-article:7192138pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:7192138pubmed:meshHeadingpubmed-meshheading:7192138-...lld:pubmed
pubmed-article:7192138pubmed:meshHeadingpubmed-meshheading:7192138-...lld:pubmed
pubmed-article:7192138pubmed:meshHeadingpubmed-meshheading:7192138-...lld:pubmed
pubmed-article:7192138pubmed:meshHeadingpubmed-meshheading:7192138-...lld:pubmed
pubmed-article:7192138pubmed:meshHeadingpubmed-meshheading:7192138-...lld:pubmed
pubmed-article:7192138pubmed:meshHeadingpubmed-meshheading:7192138-...lld:pubmed
pubmed-article:7192138pubmed:meshHeadingpubmed-meshheading:7192138-...lld:pubmed
pubmed-article:7192138pubmed:meshHeadingpubmed-meshheading:7192138-...lld:pubmed
pubmed-article:7192138pubmed:meshHeadingpubmed-meshheading:7192138-...lld:pubmed
pubmed-article:7192138pubmed:meshHeadingpubmed-meshheading:7192138-...lld:pubmed
pubmed-article:7192138pubmed:meshHeadingpubmed-meshheading:7192138-...lld:pubmed
pubmed-article:7192138pubmed:meshHeadingpubmed-meshheading:7192138-...lld:pubmed
pubmed-article:7192138pubmed:year1980lld:pubmed
pubmed-article:7192138pubmed:articleTitleMetabolism of fentiazac.lld:pubmed
pubmed-article:7192138pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7192138pubmed:publicationTypeComparative Studylld:pubmed